

Madagascar

Tuberculosis profile

Population 2016

25 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	13 (7.9–20)	54 (32–82)
Mortality (HIV+TB only)	0.61 (0.27–1.1)	2.4 (1.1–4.3)
Incidence (includes HIV+TB)	59 (38–84)	237 (153–338)
Incidence (HIV+TB only)	1.4 (0.62–2.4)	5.6 (2.5–9.8)
Incidence (MDR/RR-TB)**	0.44 (0.081–0.79)	1.8 (0.32–3.2)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0–14 years	> 14 years	Total
Females	3.8 (2.3–5.3)	19 (11–26)	23 (14–32)
Males	3.8 (2.3–5.3)	32 (20–45)	36 (22–51)
Total	7.6 (4.6–11)	51 (31–71)	59 (38–84)

TB case notifications, 2016	
Total cases notified	29 385
Total new and relapse	29 001
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	46%
- % pulmonary	79%
- % bacteriologically confirmed among pulmonary	88%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	49% (34–76)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.25 (0.12–0.4)

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive		99	<1%
- on antiretroviral therapy		97	98%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number****
Estimated MDR/RR-TB cases among notified pulmonary TB cases			210 (6–420)
Estimated % of TB cases with MDR/RR-TB	0.49% (0–1.1)	5.9% (0–15)	
% notified tested for rifampicin resistance	2%	45%	1 428
MDR/RR-TB cases tested for resistance to second-line drugs		40	
Laboratory-confirmed cases		MDR/RR-TB: 40, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 15, XDR-TB: 0	

Treatment success rate and cohort size		Success	Cohort
New cases registered in 2015		82%	26 216
Previously treated cases registered in 2015		71%	2 370
HIV-positive TB cases registered in 2015			
MDR/RR-TB cases started on second-line treatment in 2014		75%	12
XDR-TB cases started on second-line treatment in 2014			

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	21%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	29% (27–32)






TB financing, 2017	
National TB budget (US\$ millions)	12
Funding source: <1% domestic, 28% international, 72% unfunded	

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed



Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2018-05-21

Data: www.who.int/tb/data